During the past decade, Yale University Digestive Diseases conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yale University Digestive Diseases" #1 sponsor was "Exact Sciences Corporation" with 2 trials, followed by "Romark Laboratories L.C." with 1 trials sponsored, "Target PharmaSolutions, Inc." with 1 trials sponsored, "University of Florida" with 1 trials sponsored and "University of North Carolina, Chapel Hill" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yale University Digestive Diseases" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator and "University of Florida" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Yale University Digestive Diseases" are "Chronic Hepatitis C" (2 trials), "Colo-rectal Cancer" (1 trials), "Colorectal Cancer" (1 trials), "Hepatitis" (1 trials) and "Hepatitis B" (1 trials). Many other conditions were trialed in "Yale University Digestive Diseases" in a lesser frequency.

Most popular intervention types in "Yale University Digestive Diseases" are "Drug" (2 trials), "Other" (2 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ribavirin" (2 trials), "All approved therapies for the treatment of Chronic Hepatitis B (CHB)" (1 trials), "Blood Sample Collection" (1 trials), "Colonoscopy" (1 trials) and "EBR/GZR (elbasvir/grazoprevir)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Yale University Digestive Diseases" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Yale University Digestive Diseases". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Yale University Digestive Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Yale University Digestive Diseases, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".